TNFRSF8 and lymphoma: Thus, CD30 is an ideal target for these lymphoma subtypes, and the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) has shown a high response rate in newly diagnosed PTCL patients (38, 39).